免化疗新辅助帕博利珠单抗联合曲妥珠单抗和帕妥珠单抗治疗HER2富集型早期乳腺癌(WSG-KEYRICHED-1):一项单臂2期试验
WSG-KEYRICHED-1是一项在德国15个乳腺癌中心开展的单臂、多中心、开放标签、假设生成性2期试验,纳入48例HER2富集型早期乳腺癌女性,给予4周期帕博利珠单抗联合双抗HER2治疗而不化疗。43例可评估患者中20例(47%)达到病理学完全缓解(单侧95%CI下限33%),未拒绝40%的无效假设(p=0.22)。48例中4例(8%)发生与研究药物相关的3-4级不良事件,无死亡。
要点
- 43例可评估患者中20例(47%)达到病理学完全缓解,单侧95%CI下限33%,未拒绝40%的无效假设(p=0.22)。
- 48例中4例(8%)发生与研究药物相关的3-4级不良事件,4例(8%)发生严重不良事件,无死亡。
- 作者认为该免化疗短程联合方案显示潜力,需启动随机试验进一步研究HER2富集型乳腺癌的免化疗免疫治疗。
核心结论
- 尽管未能拒绝无效假设,WSG-KEYRICHED-1试验提示短程免化疗的帕博利珠单抗联合双抗HER2治疗在HER2富集型乳腺癌中具有潜力,需启动随机试验研究免化疗免疫治疗。
研究设计与样本
- WSG-KEYRICHED-1为单臂、多中心、开放标签、假设生成性2期试验,在德国15个乳腺癌中心开展。
- 纳入18岁及以上、既往未治疗、临床分期T1c-T3、N0-N2、M0、原发单侧早期浸润性乳腺癌、局部确认HER2免疫组化评分2+或3+、激素受体阳性或阴性的女性。
- 经PAM50中心确认HER2富集型且ECOG体能状态0-1的患者接受4周期静脉帕博利珠单抗200 mg每3周共12周、曲妥珠单抗生物类似药ABP 980(8 mg/kg负荷剂量后6 mg/kg每3周共12周)和帕妥珠单抗(840 mg负荷剂量后420 mg每3周共12周)。
- 主要终点为病理学完全缓解(定义为ypN0或ypT0/is)比例,在完整分析集中评估,即至少接受一剂试验治疗且在试验治疗结束后3周内完成中心肿瘤评估的患者。
- 2020年9月2日至2021年5月5日纳入48例女性,其中4例未手术、1例仅有局部病理学完全缓解评估,故43例纳入完整分析集;中位随访8.6个月(IQR 8.3-9.0)。
主要发现
- 43例中20例(47%)经中心评估达到病理学完全缓解,单侧95%CI下限33%,未能拒绝40%病理学完全缓解的无效假设(p=0.22)。
- 48例中4例(8%)发生研究者判定与药物治疗相关的3-4级不良事件,最常见的3-4级不良事件为丙氨酸氨基转移酶升高(n=1)、药物超敏反应(n=1)、肾炎(n=1)和惊恐发作(n=1)。
- 48例中4例(8%)发生严重不良事件,分别为药物超敏反应(n=1)、惊恐发作(n=1)、发热(n=1)和COVID-19(n=1)。
- 48例中3例(6%)因不良事件停用或推迟帕博利珠单抗,无死亡发生。
关键数值与推荐
- 主要终点预设:至少52.2%的患者达到病理学完全缓解,才能支持试验治疗后病理学完全缓解比例高于40%且具统计学显著性。
- 实际43例中20例(47%)达到病理学完全缓解,单侧95%CI下限33%,p=0.22,未拒绝无效假设。
临床怎么用
- 作者认为该免化疗短程帕博利珠单抗联合双抗HER2方案显示潜力,需启动随机试验研究HER2富集型乳腺癌的免化疗免疫治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Accumulating evidence indicates that about 30-40% of patients with HER2-positive early breast cancer might achieve excellent outcomes without chemotherapy. Therefore, we aimed to test the pathological complete response after the addition of pembrolizumab to dual anti-HER2 blockade and omission of chemotherapy in patients with HER2-enriched breast cancer. METHODS: WSG-KEYRICHED-1 was a single-arm, multicentre, open-label, hypothesis-generating phase 2 trial done at 15 breast cancer centres in Germany. Women aged 18 years and older, with previously untreated clinical stage T1c-T3, N0-N2, M0, primary unilateral early invasive breast cancer, and locally confirmed HER2 immunohistochemistry score 2+ or 3+ status, and hormone receptor-positive or receptor-negative status, were enrolled. Women with centrally confirmed HER2-enriched subtype by prediction analysis of microarrays 50 gene set (PAM50) and an Eastern Cooperative Oncology Group performance status of 0-1 were allocated to four cycles of intravenous pembrolizumab (200 mg every 3 weeks for 12 weeks), intravenous trastuzumab biosimilar ABP 980 (8 mg/kg loading dose, then 6 mg/kg every 3 weeks for 12 weeks), and intravenous pertuzumab (840 mg loading dose, then 420 mg every 3 weeks for 12 weeks). The primary outcome was the proportion of patients with a pathological complete response (defined as ypN0 or ypT0/is), assessed in the full analysis set, which included all patients who had at least one dose of trial treatment and had central tumour assessment within 3 weeks after the end of trial treatment. For the primary endpoint to be met, at least 52·2% of patients had to have a pathological complete response to support the hypothesis that the proportion of patients with pathological complete response after trial treatment would be higher than 40% with statistical significance. Safety was analysed in all patients who had at least one dose of trial treatment. The study is registered with ClinicalTrials.gov, NCT03988036, and has been completed. FINDINGS: Between Sept 2, 2020, and May 5, 2021, 48 women were enrolled, of whom four did not have surgery, and one had only a local pathological complete response assessment. Therefore, 43 patients with central pathological complete response assessment were included in the full analysis set. Median follow-up was 8·6 months (IQR 8·3-9·0). 20 (47%) of 43 patients had a pathological complete response by central assessment (lower bound of the one-sided 95% CI 33%), thus the null hypothesis (40% pathological complete response) could not be rejected (p=0·22). Four (8%) of 48 patients had grade 3-4 adverse events deemed related to drug treatment. The most common grade 3-4 adverse events were increased alanine aminotransferase (n=1), drug hypersensitivity (n=1), nephritis (n=1), and panic attack (n=1). Serious adverse events occurred in four (8%) of 48 patients, which were drug hypersensitivity (n=1), panic attack (n=1), pyrexia (n=1), and COVID-19 (n=1). Pembrolizumab was discontinued or postponed due to adverse events in three (6%) of 48 patients. No deaths occurred. INTERPRETATION: Although the null hypothesis could not be rejected, the WSG-KEYRICHED-1 trial highlights the potential of a short chemotherapy-free combination of pembrolizumab with dual anti-HER2 therapy, warranting the initiation of randomised trials investigating the immunotherapy without chemotherapy in patients with HER2-enriched breast cancer. FUNDING: Merck Sharp & Dohme and NanoString Technologies.
引用
- Kuemmel S, Graeser M, Schmid P, et al. Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial. Lancet Oncol. 2025. PMID: 40318646. doi:10.1016/S1470-2045(25)00097-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。